JL1108ES: Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy

Full author listing

Authors: B.J. Rimel, MD,1 Dana Chase, MD, FACOG,2 Jessica Perhanidis, MPH,3 Armen A. Ghazarian, PhD,4 Ella Xiaoyan Du, MSc,5 Travis Wang, MSc,5 Jinlin Song, PhD,5 Amanda K. Golembesky, PhD,6 Jean Hurteau, MD,3 Ritu Salani, MD,7 Bradley J. Monk, MD8

Affiliations: 1Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2, Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA (previously: Arizona Center for Cancer Care, Phoenix, AZ, USA); 3GSK, Waltham, MA, USA; 4GSK, Washington, DC, USA; 5Analysis Group, Los Angeles CA, USA; 6GSK, Durham, NC, USA; 7Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 8HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA